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To the Editor: Interferon beta is a widely prescribed recombinant-protein therapy with a
well-established favorable safety profile.1 Here, we describe an unexpectedly high number
of cases of thrombotic microangiopathy associated with severe or malignant hypertension in
four patients with multiple sclerosis who were receiving therapy with recombinant interferon
beta in South Scotland. A detailed review of the case histories of these patients, including a
genetic analysis, did not identify any other causal factor for this condition, and an analysis of
pharmacy records revealed a significant association with a common manufacturing source of
interferon beta (Rebif, Merck) (Fig. 1, and the Supplementary Appendix, available with the
full text of this letter at NEJM.org).
The regulatory authorities in the United Kingdom received six additional spontaneous
reports of disorders related to thrombotic microangiopathy and interferon beta, all associated
with the same manufacturer (for details, see the Supplementary Appendix). In December
2013, the Medicines and Healthcare Products Regulatory Agency (MHRA) issued a drug-
safety update regarding a possible link between interferon beta and thrombotic
microangiopathy.2 In April 2009, the manufacturer of Rebif added a warning to the package
insert about a possible association with thrombotic microangiopathy, which was specifically
defined as the hemolytic–uremic syndrome and thrombotic thrombocytopenic purpura
(HUS/TTP).
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We requested details regarding the geographical and temporal distribution of the HUS/TTP
reports. Consistent with our observations in the United Kingdom, very few cases were
reported globally in the first 9 years of safety monitoring. However, there has been a recent
increase in reports from countries that share the same formulation as that used in the United
Kingdom.3 Substantial caution is required in the interpretation of spontaneous reports of
adverse drug reactions, since such reports are voluntary, are potentially subject to
underreporting, and may be influenced by many factors, including the severity of the drug
reaction, the diagnostic classification, and the degree of publicity. However, we did not
detect such patterns or trends in the safe ty data from a similar recombinant interferon beta
product, suggesting that further investigation of the association with changes in
manufacturing may be worthwhile. We have raised these concerns with the manufacturer
and regulatory authorities.
The patients in our analysis share important clinical features (for details, see the
Supplementary Appendix). First, all the patients presented after years of well-tolerated
treatment with inter-feron beta, making an association difficult to recognize. Second,
fulminant presentation was associated with severe hypertension. Third, despite the
emergency presentation, retrospective review identified chronic changes in all renal-biopsy
specimens and a prodrome in three of the four patients with features that included newly
diagnosed hypertension, hematologic abnormalities, and renal impairment in the months
before diagnosis. We subsequently identified a similar prodrome in a recent fatal case in the
United Kingdom. Thrombotic microangiopathy is therefore a serious and potentially fatal
complication that has emerged late in the lifetime of recombinant inter-feron beta therapy.
Early manifestations of this complication may be recognizable with increased vigilance,
with the potential to mitigate severity.
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Figure 1. Cases of Thrombotic Microangiopathy Associated with a Common Manufacturing
Source of Interferon Beta
Shown are renal-biopsy specimens obtained from four patients receiving recombinant
interferon beta therapy in South Scotland in whom thrombotic micro-angiopathy was
diagnosed during an 18-month period (Panels A through D). All four specimens show
arteriolar luminal obliteration with swollen endothelium and fibrin (arrows; hematoxylin and
eosin and silver staining [Panels A, B, and D] and Martius scarlet blue [MSB] staining
[Panel C]). All four patients were treated with recombinant interferon beta from the same
manufacturer, as confirmed by tracing of drug batches. The Venn diagram shows the overlap
of 10 batches prescribed to patients in the year before the presentation of the index case
(Panel E).
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